Last edition
News about "HUTCHMED, China"
Hutchmed Grants GSK Worldwide Rights to KRAS-EGFR Cancer Drug Candidate HMPL-A830
Hutchmed and GSK partner to advance HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumours.
Hutchmed China | 04/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members